NCT01246635终止不适用
A Prospective, Multi-Center, Randomized, Single-Blind, Controlled Study Comparing the Trufit CB (Cartilage Bone) Implant to Microfracture for the Treatment of Patients With Single, Isolated Defects of the Knee
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 153
- 试验地点
- 14
- 主要终点
- Percent change in the Knee injury and Osteoarthritis Outcome Score (KOOS) from baseline
研究概览
简要总结
The purpose of this clinical study is to demonstrate the effectiveness and safety of the Trufit CB (Cartilage Bone) implant for the treatment of single, isolated cartilage defects of the knee compared to Microfracture.
详细描述
Up to 315 subjects, ages 18 years and older with a single, isolated cartilage defect of the knee will be randomized in a 1:1:1 ratio to 1 of 3 treatment groups:
- Trufit CB Implant with rehabilitation protocol;
- Trufit CB Implant with rehabilitation protocol;
- Microfracture with rehabilitation protocol
Rehabilitation program may be standard (6 weeks touch weight to full weight bearing) or accelerated (2 weeks touch weight to full weight bearing).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of providing informed consent;
- •Eighteen (18) years or older and skeletally mature on the date of study enrollment;
- •Willing and able to attend all follow up visits and complete all study related procedures and evaluations including, but not limited to adhering to the rehabilitation protocol;
- •Single, isolated cartilage defect (ICRS Grade III - IV) in the knee (medial or lateral femoral condyle or trochlea) that is ≥ 1cm2 (10 mm) and ≤ 2cm2 (20 mm) in area and requiring a maximum of 2 implants (if randomized to TRUFIT CB); Note: Lesion size should be assessed as the product of the longest diameter and its perpendicular applied at the widest portion of the lesion.
- •Candidate for cartilage repair surgery as a result of a single, isolated symptomatic cartilage lesion;
- •Presents with stable health at the time of study enrollment;
- •BMI of ≤ 32.
排除标准
- •Female of child-bearing potential who is pregnant or plans to become pregnant over the course of the study;
- •History of alcohol or drug abuse;
- •Presents with patellofemoral instability or other anatomical malalignment in the study knee;
- •Any diagnosis that would preclude the patient from successfully completing the study rehabilitation protocols;
- •Unable or unwilling to follow post operative procedures (e.g. rehabilitation protocol);
- •Received one or more intra-articular steroid injections in the study knee within the previous 3 months;
- •Presents with ipsilateral hip disease, as determined by pain or restricted range of motion upon physical examination;
- •Treated with either an investigational device or drug within one (1) month of study enrollment, or plans to be treated with an investigational device or drug in the next 24 months;
- •Diagnosed rheumatoid arthritis, ankylosing spondylitis (Bechterew syndrome), or calcium pyrophosphate dihydrate disease(chondrocalcinosis);
- •History of severe vascular or neurological disease, uncontrolled diabetes, or is immunosuppressed (e.g. HIV positive);
- •Musculoskeletal disease, including degenerative bone diseases such as osteochondritis dissecans and osteonecrosis;
- •Pathologic conditions of the bone (e.g. osteoporosis, cystic changes, hyperparathyroidism, Paget's Disease, hypercalcemia, prolonged use of steroids);
- •Active infection, or evidence thereof, at the lesion site;
- •Requires the use of any medication(s) or treatment(s) known to have an effect on bone metabolism (e.g. bisphosphonates, chemotherapeutic or immunosuppressive agents);
- •Requires concomitant osteotomy, partial lateral meniscectomy or complete meniscectomy; Note: Concomitant ACL reconstruction or revision, as well as meniscal repair and partial medial meniscectomies are permitted under the study protocol.
- •Has undergone an ACL reconstruction, osteotomy, chondral resurfacing procedure or partial meniscectomy (≤ central third of the meniscus) in the last year and has not completed at least 6 months of rehabilitation since such surgery; Note: Patients who have undergone these procedures within the last year and have completed at least 6 months of rehabilitation are eligible to participate in the study.
- •Any active, implanted medical device (e.g. cochlear implant) or metallic implant (other then dental work) that may interfere with Magnetic Resonance Imaging (MRI);
- •Any condition (e.g. claustrophobia) that may interfere with the patient's ability to undergo MRI;
- •Diagnosis requiring placement of an active implant (e.g. cardiac pacemaker, vagus nerve stimulator, etc.) within the next 24 months.
研究组 & 干预措施
• Microfracture with rehabilitation
Active Comparator
干预措施: Microfracture if the knee (Procedure)
TRUFIT CB with accelerated rehab.
Experimental
干预措施: Trufit CB (Cartilage Bone) Implant (Device)
TRUFIT CB with standard rehab.
Experimental
干预措施: Trufit CB (Cartilage Bone) Implant (Device)
结局指标
主要结局
Percent change in the Knee injury and Osteoarthritis Outcome Score (KOOS) from baseline
时间窗: 6 months post-procedure
次要结局
- Magnetic resonance evaluation of cartilage and underlying bone using the MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) scale(12 and 24 months post-procedure)
- Difference in Pain Scores on the Visual Analog Scale from baseline at all post operative time-points.(2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure)
- Proportion of subjects (compared to baseline) with cartilage classifications within the four groups defined by the International Cartilage Repair Society (ICRS) scoring system(24 months post-procedure)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure)
- Percent improvement from baseline in the KOOS Knee Survey Score at all time-points(2 weeks, 6, weeks, 3 months, (6 months - primary measure), 12 months and 24 months post-procedure)
- Positive change in activity level from baseline to each visit, as measured by the Tegner Activity Scale at all time-points.(2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure)
- Histological evaluation of cartilage(24 months post-procedure)
研究者
研究点 (14)
Loading locations...
相似试验
Unknown
2 期
A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung CancerNon Small Cell Lung CancerNCT04398940Chia Tai Tianqing Pharmaceutical Group Co., Ltd.71
已完成
不适用
AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F IDSurgical WoundNCT03193021Cardiva Medical, Inc.204
已完成
2 期
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's DiseaseEarly-stage Parkinson's DiseaseNCT04658186UCB Biopharma SRL496
已完成
2 期
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate CancerProstatectomyOligometastatic Prostate CancerAbirateroneNCT04992026The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School130
已完成
2 期
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationChronic Obstructive Pulmonary DiseaseNCT01332097Mereo BioPharma183